结直肠癌患者的基因组表征
Marwa Mahdouani1, Drenushe Zhuri2, Fulya Dusenkalkan2
1Laboratory of Human Cytogenetics, Molecular Genetics, and Reproductive Biology, Farhat Hached University Hospital, Sousse, Tunisia. marwamahdouani95@gmail.com.
Hereditary cancer in clinical practice
|September 27, 2025
概括
下一代测序发现了土耳其家族遗传性结直肠癌 (CRC) 的新遗传变异. 这有助于对林奇综合征和家族腺瘤多重症的诊断,改善了患者管理.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 遗传性结直肠癌 (CRC) 占病例的5-10%.
- 林奇综合征 (LS),家族腺多重症 (FAP) 和MUTYH相关多重症 (MAP) 是已知的遗传原因.
- 其他CRC遗传遗传因素仍未得到充分研究.
研究的目的:
- 在23个土耳其家庭中调查CRC的遗传原因.
- 使用下一代测序 (NGS) 进行增强的诊断.
- 在遗传性CRC综合征中识别生殖系致病变体 (gPV).
主要方法:
- 选择了具有个人/家族CRC或多病史的患者.
- 使用TruSight®癌症和Qiaseq面板进行基因测试.
- 雇员 Illumina NextSeq NGS平台用于变种检测.
主要成果:
- 确定了23种变种,包括10种致病性/可能致病性 (5种新型).
- 在MLH1,MSH6,PMS2 (与LS相关) 和APC (与FAP相关) 基因中检测到gPV.
- 在像MUTYH,ATM和CHEK2.2这样的基因中发现了13种不确定的变异 (VUS).
结论:
- 在遗传性CRC中,NGS有效识别生殖系变异.
- 需要进一步的功能研究来确定VUS的致病性.
- 这些发现有助于改善遗传性CRC的诊断和管理.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


